A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers. MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #ESMO26. The vaccine targets KRAS mutations, which are found in more than 90% of pancreatic cancers. 99% of patients receiving the vaccine developed cancer-fighting immune T cells. Patients with the strongest immune responses had the lowest recurrence rates. “Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” says Dr. O’Reilly. “This gives hope for people with pancreatic cancer who have been out of effective treatments when their disease returns.” Learn more: bit.ly/3VSsO3h

Coming up at #ESMO26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma. 🗓️ Friday, October 23 | 2:32 p.m. CEST

Through a recent collaboration, Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence are making precision oncology expertise more accessible within clinicians’ everyday workflows. The collaboration brings OpenEvidence and MSK's OncoKB™ knowledge base together to help deliver trusted, evidence-based guidance when and where it’s needed most. Watch to learn more ⬇️

When the immune system is weakened by cancer treatment — especially by a stem cell or bone marrow transplant (BMT) for blood cancer — common viruses like herpes simplex virus (HSV) can become a serious problem. For someone who is immunocompromised, an HSV infection can mean dealing with large, painful sores that resist the usual therapies and ultimately lead to more critical medical conditions. The good news: The @FDA recently approved #pritelivir (Hovilpri) for HSV infection in immunocompromised patients, including those who are undergoing cancer treatment. The study that resulted in the drug’s approval was co-led by Dr. @GenPapaMD, Clinical Director for Infectious Diseases at MSK, and Dr. June Lee, an infectious disease specialist at MSK, among others. Learn more: bit.ly/4eLLnMO

New research from MSK uncovers an unknown role for immune cells in fueling triple-negative breast cancer; identifies a new strategy for fighting leptomeningeal metastases; finds trastuzumab deruxtecan shows enhanced benefit for patients with ERBB2 mutations in breast cancer; and more: bit.ly/4sfO6nf

🚨: The @FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage 2 or 3 rectal cancer whose tumors have specific genetic characteristics known as mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H). The approach, developed at MSK by gastrointestinal medical oncologists Dr. Andrea Cercek (@AndreaCercek) and Dr. Luis Diaz Jr. (@ldiaz1971), uses immunotherapy alone to harness the body’s own immune system to fight cancer. This allows some patients to skip standard treatment for rectal cancer, which includes surgery, radiation, and chemotherapy, and can have life-altering consequences for bowel and urinary function, as well as fertility. Learn more: bit.ly/4zEQoil

Specialists at MSK know how to modify tests and treatment protocols to navigate the special needs of people who have cancer during pregnancy. Beyond the medical expertise, MSK also offers emotional support for expectant mothers facing a heartbreaking circumstance. “We are seeing this situation more often because of the rise in certain cancers among younger people,” says MSK psychologist Dr. Amanda Balakirsky. “Being pregnant with cancer can cause a lot of grief and feelings of isolation. We try to normalize the experience as best we can, to help them adjust from what they were expecting in their pregnancy and feeling different from their peers.” Learn more about how they helped one patient and her now 1.5-year-old son: bit.ly/4engGNV

We're proud to share that Dr. Ross Levine, Chief Scientific Officer at MSK and Dr. @dana_peer, Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) at MSK, have been elected to the @theNAMedicine. With these latest appointments, 30 MSK faculty members have now received this prestigious honor. Learn more about these two elections: bit.ly/3VWdHWq

Researchers at MSK and their collaborators are gaining new insights into cancer cachexia, a wasting syndrome that affects nearly half of all patients. Findings in @NatureMedicine could help predict which patients are most at risk and help facilitate timely support and interventions. Learn more: bit.ly/4yhYfl3

#Lungcancer, both small cell lung cancer (#SCLC) and non-small cell lung cancer (#NSCLC), is the second-most common cancer in the United States. "Lung adenocarcinoma, a type of NSCLC, is the most common type of lung cancer, and when caught at an early stage, it can be highly treatable. And for patients with stage one disease, surgery can often be curative," says Dr. David Jones (@JonesDavid2013), MSK's Chief of Thoracic Surgery. "If the cancer has spread to nearby lymph nodes, additional treatment may be recommended to reduce the risk of recurrence." Learn more about advances in lung cancer treatments and the advantages of coming to MSK when you are first diagnosed: bit.ly/3VLzf8b

DYK: The most common signs and symptoms of lung cancer are the same in men and women? To name a few: 🔹 A persistent cough, including coughing up blood 🔹 Wheezing or shortness of breath 🔹 Chest pain 🔹 Hoarseness 🔹 Unexplained weight loss MSK thoracic oncologist Dr. Helena Yu also shares why lung cancer is more common in women than men in younger age groups and why people get lung cancer even if they’ve never smoked: bit.ly/4BjXKts

A new MSK study co-authored by MSK's @StadlerZsofia and Dr. Luis Diaz Jr., published in @CC_AACR, found that limiting genetic testing to patients under 50 would have missed 72% of those with inherited cancer mutations. Knowing about these mutations can help guide treatment and help family members understand their cancer risk. Learn more: bit.ly/4jTtgbf